

# NAMS News



## Abstract Submission Deadline is April 30

All are invited and encouraged to share their work in the field of menopause by submitting scientific abstracts (at <http://www.menopause.org/meetings/abstractsubmission.aspx>) for consideration by April 30th. The top abstracts will be presented from the podium in a Scientific Session held during the 2010 NAMS Annual Meeting. All other abstract submissions will be considered for poster presentation during the Poster Session. Accepted posters will be eligible for one of four available poster prizes. In addition, all abstracts presented at the NAMS Annual Meeting will be published in *Menopause*.

## Why Earn the NCMP Certification?

Because your patients deserve the best! A decade ago, NAMS set the standard for menopause practice: the NAMS Certified Menopause Practitioner (NCMP) certification. There are over 500 NCMPs worldwide. Will 2010

### NAMS Central Office

The North American Menopause Society  
5900 Landerbrook Drive, Suite 390, Mayfield Heights, OH 44124

Phone: 440/442-7550 • Fax: 440/442-2660

E-mail Address: [info@menopause.org](mailto:info@menopause.org)

Web Site: <http://www.menopause.org>

## Future NAMS Annual Meetings

### 21st NAMS Annual Meeting

October 6-9, 2010 • Chicago, IL

### 22nd NAMS Annual Meeting

September 21-24, 2011 • Washington, DC

### 23rd NAMS Annual Meeting

October 3-6, 2012 • Orlando, FL

### 24th NAMS Annual Meeting

October 9-12, 2013 • Dallas, TX

be the year that you join this prestigious group? For complete information about sitting the exam, including locations and application deadlines, please download the *2010 Candidate Handbook* at <http://www.menopause.org/compexam.aspx>.

## Latest NAMS Hormone Therapy Position Statement Published in 2010

“Estrogen and Progestogen use in Postmenopausal Women: 2010 Update of 2008 Position Statement of The North American Menopause Society” was published in the March/April 2010 issue of the Society’s official journal, *Menopause*. Each section of the previous paper (2008) was reviewed by an illustrious Advisory Panel made up of clinicians and researchers expert in this area of women’s health, using new studies and findings. Specifically, the sections on breast cancer, cognitive aging/decline and dementia, coronary heart disease, stroke, and discontinuance received special attention in light of recently published literature. New sections were added on ovarian and lung cancer. A PDF is available on the NAMS Web site at [www.menopause.org/aboutmeno/consensus.aspx](http://www.menopause.org/aboutmeno/consensus.aspx).

### ADVERTISERS’ INDEX

#### Bayer HealthCare Pharmaceuticals Inc.

Angeliq .....IFC, 1-2

North American Menopause Society, The ....OBC

#### Novo Nordisk Pharmaceuticals, Inc.

Vagifem .....16-18

#### Pfizer Inc.

Premarin .....5-7